Compare American Tower Corp (AMT) vs Axogen Inc (AXGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Axogen Inc — how do they compare? American Tower Corp trades at $172.32 (market cap $79.00B), while Axogen Inc trades at $48.76 (market cap $2.61B). The key difference: American Tower Corp is far larger — about 30.3× Axogen Inc's market cap, and American Tower Corp pays a 4.12% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AMT | AXGN | |
|---|---|---|
Market Cap | $79.00B | $2.61B |
Sector | Real Estate | Technology |
52-Week High | $211.88 | $48.48 |
52-Week Low | $162.11 | $14.16 |
Enterprise Value | $122.53B | $2.52B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $169.11, down 1.99% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.86 exceeding the $1.57 estimate. Revenue trends show steady growth from $10.1B in 2024 to $10.6B in 2025, with net income margins improving to 23.76%. Recent news highlights strong Q2 2026 results and institutional buying activity.
Wall Street maintains strong bullish sentiment with 39 buy ratings and a $206.17 price target representing 22% upside potential. Key risks include interest rate sensitivity and DISH Network churn impacts. The stock offers defensive characteristics with resilient telecom demand and 5G/6G growth catalysts, though high debt levels and bearish technical signals warrant caution near-term.
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
